Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:ONCS

OncoSec Medical (ONCS) Stock Price, News & Analysis

OncoSec Medical logo

About OncoSec Medical Stock (NASDAQ:ONCS)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
$0.20
$0.94
52-Week Range
N/A
Volume
52.49 million shs
Average Volume
2.22 million shs
Market Capitalization
$1.26 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

OncoSec Medical Incorporated, a late-stage immuno-oncology company, focuses on designing, developing, commercializing intra-tumoral DNA-based therapeutics to stimulate and augment anti-tumor immune responses for the treatment of cancer. The company's product pipeline includes KEYNOTE-695, which is in Phase 2 trial for the treatment of advanced melanoma; TAVO + SARS-CoV-2 spike glycoprotein, which is in Phase 1 clinical trial for the treatment of COVID-19; and TAVO + epacadostat + pembrolizumab, which is in Phase 1 clinical trial for the treatment of squamous cell carcinoma head and neck cancer. Its pipeline also comprises TAVO +nivolumab, which is in Phase 2 clinical trial for the treatment of breast cancer; TAVO + CXCL9 for the treatment of solid tumors; and OMS-100 and OMS-102, which are in Phase 2 clinical trial for the treatment of metastatic melanoma. OncoSec Medical Incorporated has clinical trial collaborations with Merck & Co., Inc. and its subsidiary in connection with the KEYNOTE-695 and KEYNOTE-890; and a research collaboration with Duke University's Center for Applied Therapeutics to evaluate TAVO in combination or sequenced with a HER2-plasmid vaccine. The company was formerly known as NetVentory Solutions Inc. and changed its name to OncoSec Medical Incorporated in March 2011. OncoSec Medical Incorporated was incorporated in 2008 and is headquartered in Pennington, New Jersey.

Receive ONCS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for OncoSec Medical and its competitors with MarketBeat's FREE daily newsletter.

ONCS Stock News Headlines

PVCT Provectus Biopharmaceuticals, Inc.
ONCS - OncoSec Medical Incorporated
Trump’s betrayal exposed
Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.
Why Is OncoSec Medical (ONCS) Stock Up 100% Today?
See More Headlines

ONCS Stock Analysis - Frequently Asked Questions

OncoSec Medical Incorporated (NASDAQ:ONCS) issued its quarterly earnings data on Tuesday, December, 14th. The biotechnology company reported ($5.50) earnings per share for the quarter, beating analysts' consensus estimates of ($8.14) by $2.64.

Shares of OncoSec Medical reverse split before market open on Wednesday, November 9th 2022. The 1-22 reverse split was announced on Wednesday, November 9th 2022. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, November 9th 2022. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some other companies that OncoSec Medical investors own include Cytokinetics (CYTK), Inovio Pharmaceuticals (INO), Anavex Life Sciences (AVXL), Sorrento Therapeutics (SRNE), XOMA (XOMA), Amarin (AMRN) and Catalyst Pharmaceuticals (CPRX).

Company Calendar

Last Earnings
12/14/2021
Today
4/19/2025
Fiscal Year End
7/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
NASDAQ:ONCS
Employees
40
Year Founded
2011

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-34,180,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$3.42 per share
Price / Book
N/A

Miscellaneous

Free Float
4,494,000
Market Cap
$1.26 million
Optionable
Not Optionable
Beta
1.99

Social Links

The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

This page (NASDAQ:ONCS) was last updated on 4/19/2025 by MarketBeat.com Staff
From Our Partners